Pluristem Therapeutics Inc. is a regenerative medicine company focusing on developing placenta-based cell therapy product candidates. The company has reported successful clinical trial data in multiple indications for its patented PLX cell product candidates, and is currently conducting late-stage trials in various indications. The PLX cells are grown using the company's proprietary three-dimensional expansion technology and can be administered to patients without tissue matching. Pluristem has a strong intellectual property position, an in-house GMP-certified manufacturing and research facility, strategic relationships with research institutions, and an experienced management team.